Patient-reported outcomes in idiopathic pulmonary fibrosis research

Chest

Volumn 142, Issue 2, 2012, Pages 291-297

  Swigris, Jeffrey J ^a   Fairclough, Diane ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASELINE DYSPNEA INDEX; BORG DYSPNEA SCALE; CONSTRUCT VALIDITY; DYSPNEA; EUROQOL 5 DIMENSION INSTRUMENT; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; INTERNAL CONSISTENCY; LAST OBSERVATION CARRIED FORWARD; MULTIVARIATE ANALYSIS OF VARIANCE; NOTE; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RASCH ANALYSIS; SCORING SYSTEM; SELF REPORT; SHORT FORM 36; ST GEORGE RESPIRATORY QUESTIONNAIRE; STATISTICAL ANALYSIS; TEST RETEST RELIABILITY; TRANSITION DYSPNEA INDEX; UNIVERSITY OF CALIFORNIA SAN DIEGO SHORT OF BREATH QUESTIONNAIRE;

EID: 84864815252     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2602     Document Type: Note

References (30)

1. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9(8):887-900. (Pubitemid 32210183)
2. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272(8):619-626. (Pubitemid 24255222)
3. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Qualification Process for Drug Development Tools. Silver Spring, MD: US Department of Health and Human Services; 2010.
4. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(1):75-81.
5. Raghu G, Brown KK, Bradford WZ, et al Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350(2):125-133. (Pubitemid 38056223)
6. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178(9):948-955.
7. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92-99.
8. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620-628.
9. King TE Jr, Albera C, Bradford WZ, et al INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374(9685):222-228.
10. Demedts M, Behr J, Buhl R, et al IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229-2242. (Pubitemid 41697286)
11. Streiner D, Norman G. Reliability. In: Health Measurement Scales: a Practical Guide to Their Development and Use. 4th ed. New York: Oxford University Press; 2008:104-126.
12. Hays R D, Anderson RT, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: Staquet M, Hays R, Fayers P, eds. Quality of Life Assessment in Clinical Trials. New York: Oxford University Press; 1998:169-182.
13. Nadorra RL, Landing BH. Pulmonary lesions in childhood onset systemic lupus erythematosus: analysis of 26 cases, and summary of literature. Pediatr Pathol. 1987;7(1):1-18. (Pubitemid 17109054)
14. Nunnally J, Bernstein J. The assessment of reliability. In: Psychometric Theory. 3rd ed. New York: McGraw-Hill; 1994:248-292.
15. du Bois RM, Weycker D, Albera C, et al. Forced vital capac ity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184(12):1382- 1389.
16. Rasch G. Probabilistic Models for Some Intelligence and Attainment Tests. Copenhagen, Denmark:Danish Institute of Educational Research; 1960.
17. Hays RD, Hadorn D. Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res. 1992;1(1):73-75.
18. Patrick DL, Chiang YP. Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. Med Care. 2000;38(suppl 9):II14-II25.
19. Nunnally J. Introduction to Psychological Measurement. New York, NY: McGraw-Hill; 1970.
20. Swigris JJ, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest. 2005;127(1):284-294. (Pubitemid 41724589)
21. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005;60(7):588-594. (Pubitemid 40966214)
22. Nishiyama O, Taniguchi H, Kondoh Y, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med. 2005;99(4):408-414. (Pubitemid 40347823)
23. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459-466.
24. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9):1231-1237.
25. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010;104(2):296-304.
26. Swigris JJ, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes. 2010;8:77.
27. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax. 2010;65(10):921-926.
28. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med. 1998;17(5-7):517-532. (Pubitemid 28118924)
29. Noble PW, Albera C, Bradford WZ, et al CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-1769.
30. Fairclough D. Models for longitudinal studies I. In: Design and Analysis of Quality of Life Studies in Clinical Trials. 2nd ed. New York, NY: CRC Press; 2010:53-81.